Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for pediatric patients with many hematological diseases. The indications for HSCT in children are well defined for acute leukemia, as well as for patients with non-malignant disease. HSCT from HLA-identical sibling or unrelated donors, such as new techniques of graft manipulation using haploidentical donor graft, provides a high chance of cure for those patients. The field of HSCT is rapidly evolving with the possibility to perform targeted immunotherapy with CAR-T cells for acute lymphoblastic leukemia, B-cell lymphomas and solid tumors. More recently, the first results of gene therapy for hereditary diseases, open new perspectives of treatment for patients with thalassemia, sickle cell disease, primary immune-deficiencies and metabolic disorders
The meeting will address all the relevant aspects of indication and results of HSCT in pediatric population, focusing on new insights on gene therapy for hereditary diseases, as well as on the newest results obtained through approaches of immunotherapy. Ethical and regulatory aspects related to these new therapies will be discussed, as well.
Recognized, outstanding international leaders will deliver the main lectures, but also high-level research talks selected from the best abstracts submitted by attendees will be presented.